Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline Review, H2 2016

Global Markets Direct
62 Pages - GMD17137
$2,000.00

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Vasomotor Symptoms of Menopause (Hot Flashes) – Pipeline Review, H2 2016, provides an overview of the Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health) pipeline landscape.

Vasomotor symptoms of menopause include hot flashes or night sweats that result from sudden opening of the blood vessels close to the skin, usually due to hormonal fluctuations in menopause and perimenopause. These symptoms are caused due to some medications, estrogen withdrawal, thyroid disease, diabetes, hyperhidrosis, anxiety and panic disorders, obesity, hormonally active tumors, chronic infections and neurological disorders.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Vasomotor Symptoms of Menopause (Hot Flashes) – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Vasomotor Symptoms of Menopause (Hot Flashes) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 5, 2 and 2 respectively.

Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health).
- The pipeline guide reviews pipeline therapeutics for Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned

EndoCeutics Inc
MenoGeniX Inc
Mithra Pharmaceuticals SA
NeRRe Therapeutics Ltd
Ogeda SA
Pherin Pharmaceuticals Inc
Radius Health Inc
TherapeuticsMD Inc

'

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Vasomotor Symptoms of Menopause (Hot Flashes) Overview 7
Therapeutics Development 8
Pipeline Products for Vasomotor Symptoms of Menopause (Hot Flashes) - Overview 8
Vasomotor Symptoms of Menopause (Hot Flashes) - Therapeutics under Development by Companies 9
Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Vasomotor Symptoms of Menopause (Hot Flashes) - Products under Development by Companies 13
Vasomotor Symptoms of Menopause (Hot Flashes) - Companies Involved in Therapeutics Development 14
EndoCeutics Inc 14
MenoGeniX Inc 15
Mithra Pharmaceuticals SA 16
NeRRe Therapeutics Ltd 17
Ogeda SA 18
Pherin Pharmaceuticals Inc 19
Radius Health Inc 20
TherapeuticsMD Inc 21
Vasomotor Symptoms of Menopause (Hot Flashes) - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Combination Products 23
Assessment by Target 24
Assessment by Mechanism of Action 26
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 32
(acolbifene hydrochloride + prasterone) - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
(estradiol acetate + progesterone) - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
ESN-364 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
Estetrol - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
FP-101 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
HBN-2 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
MNGX-100 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
NT-814 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
PH-80HF - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
Q-122 - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
RAD-1901 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
Vasomotor Symptoms of Menopause (Hot Flashes) - Dormant Projects 51
Vasomotor Symptoms of Menopause (Hot Flashes) - Discontinued Products 53
Vasomotor Symptoms of Menopause (Hot Flashes) - Product Development Milestones 54
Featured News & Press Releases 54
Dec 05, 2016: TherapeuticsMD Announces Positive Top-Line Results from Pivotal Phase 3 Replenish Trial in Postmenopausal Women with Moderate to Severe Vasomotor Symptoms (VMS) Treated with TX-001HR 54
Sep 14, 2016: Euroscreen SA: Completes Enrollment in Phase II trial of lead candidate ESN364 in Menopausal Hot Flashes 55
Jul 19, 2016: EUROSCREEN opens US-IND for ESN364 on three Phase II trials 56
Apr 01, 2016: Radius to provide an update on RAD1901 at the ENDO 2016 Annual Meeting 56
Oct 13, 2015: TherapeuticsMD Completes Enrollment in Phase 3 Clinical Trial of Bio-identical Oral Combination of Estradiol and Progesterone Product Candidate 56
Sep 23, 2015: Euroscreen launches Phase 2 clinical trial with ESN364 as the first and unique non-hormonal causal treatment for menopausal Hot Flashes 57
Jan 06, 2014: TherapeuticsMD Announces Milestone Achievement of 50th Site for Phase 3 Clinical Trial of TX 12-001HR to Treat Symptoms of Menopause and Provide Endometrial Protection 57
Oct 18, 2013: TherapeuticsMD Poster Wins First-Place Prize at the North American Menopause Society 2013 Annual Meeting 58
Jun 19, 2010: Radius Presents Positive Phase IIa Study Results Of RAD1901 In Reducing Menopausal Hot Flashes 58
Jun 08, 2008: Radius Presents Preclinical Study Of RAD1901 At The Endocrine Society 2007 Annual Meeting 59
Appendix 61
Methodology 61
Coverage 61
Secondary Research 61
Primary Research 61
Expert Panel Validation 61
Contact Us 61
Disclaimer 62

List of Tables
Number of Products under Development for Vasomotor Symptoms of Menopause (Hot Flashes), H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Comparative Analysis by Late Stage Development, H2 2016 10
Comparative Analysis by Clinical Stage Development, H2 2016 11
Comparative Analysis by Early Stage Development, H2 2016 12
Products under Development by Companies, H2 2016 13
Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline by EndoCeutics Inc, H2 2016 14
Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline by MenoGeniX Inc, H2 2016 15
Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline by Mithra Pharmaceuticals SA, H2 2016 16
Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline by NeRRe Therapeutics Ltd, H2 2016 17
Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline by Ogeda SA, H2 2016 18
Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline by Pherin Pharmaceuticals Inc, H2 2016 19
Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline by Radius Health Inc, H2 2016 20
Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline by TherapeuticsMD Inc, H2 2016 21
Assessment by Monotherapy Products, H2 2016 22
Assessment by Combination Products, H2 2016 23
Number of Products by Stage and Target, H2 2016 25
Number of Products by Stage and Mechanism of Action, H2 2016 27
Number of Products by Stage and Route of Administration, H2 2016 29
Number of Products by Stage and Molecule Type, H2 2016 31
Vasomotor Symptoms of Menopause (Hot Flashes) - Dormant Projects, H2 2016 51
Vasomotor Symptoms of Menopause (Hot Flashes) - Dormant Projects (Contd..1), H2 2016 52
Vasomotor Symptoms of Menopause (Hot Flashes) - Discontinued Products, H2 2016 53

List of Figures
Number of Products under Development for Vasomotor Symptoms of Menopause (Hot Flashes), H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Comparative Analysis by Clinical Stage Development, H2 2016 11
Assessment by Monotherapy Products, H2 2016 22
Number of Products by Targets, H2 2016 24
Number of Products by Stage and Targets, H2 2016 24
Number of Products by Top 10 Mechanism of Actions, H2 2016 26
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 26
Number of Products by Routes of Administration, H2 2016 28
Number of Products by Stage and Routes of Administration, H2 2016 28
Number of Products by Molecule Types, H2 2016 30
Number of Products by Stage and Molecule Types, H2 2016 30

$2,000.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

Please contact us at [email protected]
or +1 212 564 2838

 

Custom Research

Contact us to speak
with your industry analyst.

[email protected] 
+1 212 564 2838

 



Discount Codes

Request Discount Codes
for reports of interest to you.

[email protected]
+1 212 564 2838